Erste Asset Management GmbH Acquires Shares of 13,500 Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Erste Asset Management GmbH bought a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 13,500 shares of the company's stock, valued at approximately $526,000.

A number of other large investors have also recently bought and sold shares of the company. FNY Investment Advisers LLC acquired a new stake in shares of Protagonist Therapeutics in the fourth quarter valued at about $38,000. Harvest Fund Management Co. Ltd acquired a new position in shares of Protagonist Therapeutics during the 3rd quarter worth approximately $69,000. KBC Group NV raised its stake in shares of Protagonist Therapeutics by 54.4% during the 4th quarter. KBC Group NV now owns 2,093 shares of the company's stock worth $81,000 after purchasing an additional 737 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Protagonist Therapeutics by 10.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company's stock valued at $121,000 after buying an additional 295 shares during the last quarter. Finally, Caprock Group LLC bought a new position in shares of Protagonist Therapeutics in the fourth quarter valued at $224,000. Institutional investors and hedge funds own 98.63% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. BMO Capital Markets increased their price target on shares of Protagonist Therapeutics from $62.00 to $72.00 and gave the company an "outperform" rating in a research note on Tuesday, March 11th. BTIG Research set a $73.00 price target on Protagonist Therapeutics in a report on Monday, March 3rd. JMP Securities restated a "market outperform" rating and issued a $58.00 price objective on shares of Protagonist Therapeutics in a research note on Friday, February 7th. HC Wainwright reissued a "buy" rating and set a $54.00 target price on shares of Protagonist Therapeutics in a report on Monday, March 10th. Finally, StockNews.com downgraded Protagonist Therapeutics from a "buy" rating to a "hold" rating in a report on Tuesday, December 10th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $62.56.

Remove Ads

Protagonist Therapeutics Stock Down 0.3 %

Shares of Protagonist Therapeutics stock traded down $0.17 during trading on Wednesday, reaching $54.35. The company's stock had a trading volume of 1,048,594 shares, compared to its average volume of 740,092. The business's 50-day moving average price is $40.25 and its 200-day moving average price is $42.39. Protagonist Therapeutics, Inc. has a 52 week low of $24.22 and a 52 week high of $60.60. The firm has a market cap of $3.34 billion, a PE ratio of 20.43 and a beta of 2.34.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its quarterly earnings data on Friday, February 21st. The company reported $1.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $2.07. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. The firm had revenue of $170.64 million during the quarter, compared to the consensus estimate of $56.65 million. Equities analysts predict that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Arturo Md Molina sold 30,514 shares of the company's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $55.74, for a total transaction of $1,700,850.36. Following the completion of the sale, the insider now directly owns 83,892 shares in the company, valued at approximately $4,676,140.08. This represents a 26.67 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director William D. Waddill sold 4,000 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $54.25, for a total value of $217,000.00. Following the sale, the director now directly owns 13,130 shares in the company, valued at approximately $712,302.50. This trade represents a 23.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 64,776 shares of company stock valued at $3,585,010 over the last 90 days. 5.40% of the stock is owned by corporate insiders.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.